Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma	Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, transitional cell carcinoma	Recruiting	Not stated	2026-02-24		NCT06657157

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Comprehensive Cancer Center Munich (CCCM)	1
Department of Urology, Augsburg University Hospital, Augsburg, Germany	1
Department of Urology, TUM Klinikum rechts der Isar, Munich, Germany	1
LMU Klinikum	34
Wuerzburg University Hospital	52

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Department of Urology, Klinikum rechts der Isar, Technical University Munich	Munich	Germany	1
Department of Urology, LMU University Hospital, Ludwig-Maximilians-University Munich	Munich	Germany	1
Department of Urology, University Hospital of Würzburg	Würzburg	Germany	1
Department of Urology, University Hosptial Augsburg	Augsburg	Germany	1